A new study has shown that patients with coexisting type 2 diabetes mellitus and prostate cancer had significantly improved overall survival if they received thiazolidinediones (Kaplan–Meier log-rank, P = 0.005) or metformin (P = 0.035) but not if they received insulin or an insulin secretagog for their diabetes. Antidiabetic therapy in these patients could, therefore, be tailored to improve their survival.